Learn More About

Who We Are

Our mission is to develop life-changing gene therapies for patients with cancer and diabetes through unique, innovative science.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and diabetes.

Genprex’s oncology drug development program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The company’s lead product candidate, REQORSA™ immunogene therapy (quaratusugene ozeplasmid), is being developed for non-small cell lung cancer (NSCLC). The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. REQORSA uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are deficient. In January 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with TagrissoIn 2021, the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Merck & Co’s Keytruda® (pembrolizumab) for patients whose disease progressed after treatment with Keytruda. GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies.


We are committed to fighting cancer and diabetes by continuing to develop unique and innovative gene therapies.


Our pioneering technologies are at the forefront of gene therapy and we stand behind our high-quality technology platform.


We have integrity and high ethical standards, and we believe in responsibly transforming the lives of those affected with cancer and diabetes.


Our commitment, excellence in technology, and integrity behind what we do enables us to be trailblazers in the effort to change the lives of patients afflicted by cancer and diabetes.


Our Team

We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.